Form 4 for ALMS ALUMIS INC.
Accepted 2025-05-06 00:00:00 ET · period of report 2025-05-02 · accession 0001415889-25-012166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-05-06 | 2025-05-02+ | ALMS | AKKARAJU SRINIVAS | Dir | P - Purchase | $4.61 | +320.3K | 3.56M | +10% | +$1.48M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-05 | P | A | 22,002 | $5.27 | 3,586,788 | I By Samsara BioCapital, L.P. | — | — | (F4) The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $5.19 to $5.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. (F2) Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2025-05-02 | P | A | 159,920 | $4.55 | 3,426,418 | I By Samsara BioCapital, L.P. | — | — | (F1) The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.97 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. (F2) Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein. |
| 3 | Common | Common Stock | 2025-05-05 | P | A | 138,368 | $4.58 | 3,564,786 | I By Samsara BioCapital, L.P. | — | — | (F3) The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.19 to $5.1899 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. (F2) Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein. |